A study published in the journal Gastroenterology and Hepatology highlights potential risks associated with GLP-1 receptor agonists, commonly prescribed for diabetes and weight loss, in patients suffering from liver cirrhosis. The findings indicate that these medications may contribute to muscle loss, a condition known as sarcopenia, which is particularly concerning for individuals with liver disease. Muscle health is vital for these patients, as loss of muscle mass can lead to reduced strength, increased risk of infections, and poorer quality of life.

The study revealed that patients with cirrhosis who were treated with GLP-1 drugs showed a greater tendency for muscle mass decline due to altered metabolism and reduced protein synthesis. While GLP-1 drugs are known for their appetite-reducing effects, they may inadvertently lead to decreased calorie and protein intake, exacerbating muscle depletion in already frail individuals. Experts emphasize that not all weight loss is beneficial, especially if it involves losing lean muscle.

To mitigate these risks, healthcare providers are advised to monitor body composition, ensure adequate protein intake, and regularly assess muscle strength in patients using GLP-1 medications. The study underscores the importance of a balanced approach in treatment, prioritizing muscle preservation alongside weight management for patients with liver cirrhosis.